Nomir Medical Technologies Investor Overview





Executive Summary:  Nomir Medical Technologies develops laser technology to address medical issues that are difficult or prohibitively expensive to treat.  Royalty revenue for products based on the Company’s patents has a market potential of several hundred million dollars.  Selex ES1, a subsidiary of Finmeccanica, has agreed to market the Company’s current product as well as to modify it to address the hospital acquired infection market.  The Company seeks additional partners and investors.


Definition of Our Business:  Nomir Medical Technologies creates and sells products and licenses technology that use specific wavelengths of laser light to treat disease without causing thermal damage. Validated by ten years of experiments and clinical trials and protected by mechanism of action2 patents,

Nomir’s photobiological effect has medical applications for several areas of human physiology including:  


Onychomycosis:  Approved by the FDA, Health Canada, and the European Union (CE-Mark), the Noveon®

NaiLaser™ provides therapy for onychomycosis (toenail fungus).  The Company is expanding sales and marketing in the United States and has existing distribution arrangements for Canada and Mexico.  Selex ES has agreed to fully-fund sales and marketing in Europe and the Middle East and is evaluating selling the laser in Asia. 

Antibiotic Resistance:  The Noveon Laser restores the effectiveness of antibiotics in treating antibiotic resistant infections such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriacea (CRE), which lead to longer patient hospital stays, increased therapy costs, and growing mortality.3  Selex is funding 100% of product development costs and forecasts royalty payments to the Company of several hundred million dollars.  

Diabetic Foot Ulcers:  Infected diabetic foot ulcers provide a pathogenic environment identical to that found in MRSA cases. The current treatment market is several billion dollars annually.  The Company has developed a prototype and is seeking $4.75 million to conduct additional human pilot studies.  Selex has an option to fund and market this product under identical royalty terms of its current definitive agreement with Nomir. 



New Opportunities: The Company has other patents/patents pending on additional photobiological effects and is seeking partners to address the following markets in return for exclusive sales rights (the Selex ES partnership model):  Oncology, obesity, accelerated skin growth (wound care and Botox replacement), and photodynamic therapy for lung diseases.    

Nomir Medical Technologies – Using Light to Treat Disease


1 Selex employs 18,000 people worldwide and has annual revenues in excess of $5 billion.

2 Mechanism of action is a key feature of drug company patent protection. The mechanism of action aspect of Nomir’s patents prevents other companies from offering similar types of solutions.   

3 Nomir’s patented mechanism of action affects the pathogens without affecting the antibiotic, allowing the antibiotic to work by disabling the resistance mechanism.  Because antibiotics already have FDA clearance, the regulatory pathways are simplified.  The FDA’s Office of Device Evaluation (ODE) reviews Nomir’s 510(k) and PMA applications.




No votes yet
Please add your rating to this item.